Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose atropine versus minus lens therapy for intermittent exotropia in children
IRCT20230626058588N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jul 2023
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atropine in Intermittent exotropia (IXT) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Angle of deviation at 3 months and Control of deviation at 3 months. Started Jul 2023; status: completed.
02
Drugs
atropine
03
Conditions
Intermittent exotropia (IXT)
Beyond the preview
Go deeper on IRCT20230626058588N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230626058588N1.